Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- 11?Hydroxysteroid 11?HSD2 mineral corticoid HSD 11B2 in born hyper tension hypo kalemia
- Product Overview:
11?-Hydroxysteroid Dehydrogenase (Type 2) (11?-HSD2) catalyzes the conversion of cortisol (hydrocortisone; Item No. 20739) to the inactive glucocorticoid cortisone (Item No. 30763), thereby protecting the mineralcorticoid receptor from glucocorticoid excess.{12000} It is primarily expressed in the kidneys, but has also been detected in the colon, salivary glands, and fetal tissues, including the placenta, and is localized to the endoplasmic reticulum.{12000,58670} Knockout of HSD11B2, the gene encoding 11?-HSD2, reduces fetal and placental growth as well as capillary development in mice.{58671} Loss-of-function mutations in HSD11B2 result in apparent mineralcorticoid excess (AME), an inborn error of metabolism characterized by hypertension, hypokalemia, and reduced plasma renin activity.{12000} Cayman’s 11?-Hydroxysteroid Dehydrogenase (Type 2) Polyclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications. The antibody recognizes 11?-HSD2 at 44 kDa from mouse samples.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.